[go: up one dir, main page]

WO2003013422A3 - Methods for the treatment and prognosis of leukemia and other cancer types - Google Patents

Methods for the treatment and prognosis of leukemia and other cancer types Download PDF

Info

Publication number
WO2003013422A3
WO2003013422A3 PCT/IL2002/000649 IL0200649W WO03013422A3 WO 2003013422 A3 WO2003013422 A3 WO 2003013422A3 IL 0200649 W IL0200649 W IL 0200649W WO 03013422 A3 WO03013422 A3 WO 03013422A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prognosis
leukemia
treatment
cancer types
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2002/000649
Other languages
French (fr)
Other versions
WO2003013422A2 (en
Inventor
Sarit Larisch
Ronit Elhasid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fund For Medical Research Development Of Infrastructure & Health Services Rambam Medical Center
FUND FOR MEDICAL RES DEV OF IN
Original Assignee
Fund For Medical Research Development Of Infrastructure & Health Services Rambam Medical Center
FUND FOR MEDICAL RES DEV OF IN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund For Medical Research Development Of Infrastructure & Health Services Rambam Medical Center, FUND FOR MEDICAL RES DEV OF IN filed Critical Fund For Medical Research Development Of Infrastructure & Health Services Rambam Medical Center
Priority to CA002456909A priority Critical patent/CA2456909A1/en
Priority to IL16024202A priority patent/IL160242A0/en
Priority to EP02760520A priority patent/EP1451218A4/en
Publication of WO2003013422A2 publication Critical patent/WO2003013422A2/en
Anticipated expiration legal-status Critical
Publication of WO2003013422A3 publication Critical patent/WO2003013422A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to methods and pharmaceutical compositions for inducing cell death by selectively inducing apoptosis in a cell which does not express or contain low amounts of ARTS and in another embodiment to methods and pharmaceutical compositions for inducing cell death in leukemic cells.
PCT/IL2002/000649 2001-08-07 2002-08-07 Methods for the treatment and prognosis of leukemia and other cancer types Ceased WO2003013422A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002456909A CA2456909A1 (en) 2001-08-07 2002-08-07 Methods for the treatment and prognosis of leukemia and other cancer types
IL16024202A IL160242A0 (en) 2001-08-07 2002-08-07 Methods for the treatment and prognosis of leukemia and other cancer types
EP02760520A EP1451218A4 (en) 2001-08-07 2002-08-07 Methods for the treatment and prognosis of leukemia and other cancer types

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31025601P 2001-08-07 2001-08-07
US60/310,256 2001-08-07

Publications (2)

Publication Number Publication Date
WO2003013422A2 WO2003013422A2 (en) 2003-02-20
WO2003013422A3 true WO2003013422A3 (en) 2004-05-21

Family

ID=23201665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000649 Ceased WO2003013422A2 (en) 2001-08-07 2002-08-07 Methods for the treatment and prognosis of leukemia and other cancer types

Country Status (4)

Country Link
EP (1) EP1451218A4 (en)
CA (1) CA2456909A1 (en)
IL (1) IL160242A0 (en)
WO (1) WO2003013422A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2552955A1 (en) * 2004-01-07 2005-08-18 Rambam Medical Center, Funds For Medical Research Development Of Infrast Ructure And Health Services Induction of apoptosis via arts-iap complexes
WO2013121428A1 (en) 2012-02-15 2013-08-22 Carmel-Haifa University Economic Corporation Ltd. ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055209A2 (en) * 2000-01-29 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel human septin and uses thereof
US6423504B1 (en) * 1998-11-16 2002-07-23 Secretary Of Agency Of Industrial Science And Technology Human-derived bradeion proteins, DNA coding for the proteins, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423504B1 (en) * 1998-11-16 2002-07-23 Secretary Of Agency Of Industrial Science And Technology Human-derived bradeion proteins, DNA coding for the proteins, and uses thereof
WO2001055209A2 (en) * 2000-01-29 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Novel human septin and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LARISCH-BLOCH ET AL.: "Selective Loss of the Transforming Growth Factor-beta Apoptotic Signalling Pathway in Mutant NRP-154 Rat Prostatic Epithelial Cells", CELL GROWTH & DIFFERENTIATION, vol. 11, January 2000 (2000-01-01), pages 1 - 10, XP002908884 *

Also Published As

Publication number Publication date
WO2003013422A2 (en) 2003-02-20
CA2456909A1 (en) 2003-02-20
EP1451218A2 (en) 2004-09-01
EP1451218A4 (en) 2006-03-08
IL160242A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
WO2004100870A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2003037060A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
AU2006254902A8 (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
TW200510413A (en) Novel pyrrolodihydroisoquinolines
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2006037052A3 (en) Modulating mxa expression
WO2006001956A3 (en) Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
WO2006010150A3 (en) Housekeeping genes and methods for identifying the same
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
TW200510398A (en) Novel compounds
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
WO2005086974A3 (en) Methods and compositions for treating cancer
WO2003013422A3 (en) Methods for the treatment and prognosis of leukemia and other cancer types
PL380665A1 (en) Pharmaceutical compositions
WO2007027344A3 (en) Compounds and methods for the treatment of cancer
WO2004026892A3 (en) Fragmentation of dna
WO2006081337A3 (en) Erastin analogues and their uses for killing cancer cells
WO2004041196A3 (en) Methods and compositions for the diagnosis of neuroendocrine lung cancer
WO2006015191A3 (en) Multicyclic lonidamine analogs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 160242

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2456909

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002760520

Country of ref document: EP

Ref document number: 2002326111

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002760520

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP